Advisors Asset Management Inc. Sells 2,136 Shares of Amgen Inc. $AMGN

Advisors Asset Management Inc. lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 109,990 shares of the medical research company’s stock after selling 2,136 shares during the period. Amgen accounts for about 0.5% of Advisors Asset Management Inc.’s investment portfolio, making the stock its 20th biggest holding. Advisors Asset Management Inc.’s holdings in Amgen were worth $31,039,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC grew its stake in shares of Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after acquiring an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC boosted its stake in Amgen by 10.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after purchasing an additional 114 shares in the last quarter. Matrix Asset Advisors Inc. NY grew its position in Amgen by 4.4% during the 2nd quarter. Matrix Asset Advisors Inc. NY now owns 101,598 shares of the medical research company’s stock worth $28,367,000 after purchasing an additional 4,284 shares during the last quarter. Vest Financial LLC increased its stake in Amgen by 44.4% during the 2nd quarter. Vest Financial LLC now owns 14,494 shares of the medical research company’s stock valued at $4,047,000 after purchasing an additional 4,456 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. increased its stake in Amgen by 0.5% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 53,433 shares of the medical research company’s stock valued at $14,919,000 after purchasing an additional 264 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Down 3.0%

AMGN stock opened at $364.65 on Wednesday. Amgen Inc. has a one year low of $261.43 and a one year high of $385.12. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The firm’s fifty day moving average is $335.74 and its 200 day moving average is $312.39. The firm has a market cap of $196.36 billion, a PE ratio of 25.63, a P/E/G ratio of 3.85 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This is a positive change from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.8%. Amgen’s payout ratio is 66.90%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Oppenheimer set a $400.00 price objective on shares of Amgen and gave the company an “outperform” rating in a report on Thursday, January 29th. Scotiabank assumed coverage on Amgen in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price target for the company. Leerink Partners increased their price objective on Amgen from $305.00 to $355.00 and gave the company an “outperform” rating in a report on Wednesday, February 4th. TD Cowen reiterated a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. Finally, BMO Capital Markets upped their price objective on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Amgen has an average rating of “Moderate Buy” and an average target price of $353.39.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the transaction, the senior vice president directly owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.69% of the stock is owned by company insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.